12
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          The nonstructural protein 3 (NSP3) of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) contains a conserved macrodomain enzyme (Mac1) that is critical for pathogenesis and lethality. There are currently no well-validated inhibitors for this protein. Here, we discovered and optimized several different classes of ligands that bind to Mac1 with low- to sub-micromolar affinity. Ligands were designed by linking together small-molecule fragments and by ultra-large library docking of 450 million molecules. Overall, we discovered 160 ligands in 119 different scaffolds, and 152 Mac1-ligand complex crystal structures were determined. Our analyses discovered selective and cell-permeable molecules, unexpected ligand-mediated protein dynamics within the active site, and key structural information that will guide future drug development for this important antiviral target.

          Abstract

          The nonstructural protein 3 (NSP3) of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) contains a conserved macrodomain enzyme (Mac1) that is critical for pathogenesis and lethality. While small-molecule inhibitors of Mac1 have great therapeutic potential, at the outset of the COVID-19 pandemic, there were no well-validated inhibitors for this protein nor, indeed, the macrodomain enzyme family, making this target a pharmacological orphan. Here, we report the structure-based discovery and development of several different chemical scaffolds exhibiting low- to sub-micromolar affinity for Mac1 through iterations of computer-aided design, structural characterization by ultra-high-resolution protein crystallography, and binding evaluation. Potent scaffolds were designed with in silico fragment linkage and by ultra-large library docking of over 450 million molecules. Both techniques leverage the computational exploration of tangible chemical space and are applicable to other pharmacological orphans. Overall, 160 ligands in 119 different scaffolds were discovered, and 153 Mac1-ligand complex crystal structures were determined, typically to 1 Å resolution or better. Our analyses discovered selective and cell-permeable molecules, unexpected ligand-mediated conformational changes within the active site, and key inhibitor motifs that will template future drug development against Mac1.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          ZINC 15 – Ligand Discovery for Everyone

          Many questions about the biological activity and availability of small molecules remain inaccessible to investigators who could most benefit from their answers. To narrow the gap between chemoinformatics and biology, we have developed a suite of ligand annotation, purchasability, target, and biology association tools, incorporated into ZINC and meant for investigators who are not computer specialists. The new version contains over 120 million purchasable “drug-like” compounds – effectively all organic molecules that are for sale – a quarter of which are available for immediate delivery. ZINC connects purchasable compounds to high-value ones such as metabolites, drugs, natural products, and annotated compounds from the literature. Compounds may be accessed by the genes for which they are annotated as well as the major and minor target classes to which those genes belong. It offers new analysis tools that are easy for nonspecialists yet with few limitations for experts. ZINC retains its original 3D roots – all molecules are available in biologically relevant, ready-to-dock formats. ZINC is freely available at http://zinc15.docking.org.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The cellular thermal shift assay for evaluating drug target interactions in cells.

            Thermal shift assays are used to study thermal stabilization of proteins upon ligand binding. Such assays have been used extensively on purified proteins in the drug discovery industry and in academia to detect interactions. Recently, we published a proof-of-principle study describing the implementation of thermal shift assays in a cellular format, which we call the cellular thermal shift assay (CETSA). The method allows studies of target engagement of drug candidates in a cellular context, herein exemplified with experimental data on the human kinases p38α and ERK1/2. The assay involves treatment of cells with a compound of interest, heating to denature and precipitate proteins, cell lysis, and the separation of cell debris and aggregates from the soluble protein fraction. Whereas unbound proteins denature and precipitate at elevated temperatures, ligand-bound proteins remain in solution. We describe two procedures for detecting the stabilized protein in the soluble fraction of the samples. One approach involves sample workup and detection using quantitative western blotting, whereas the second is performed directly in solution and relies on the induced proximity of two target-directed antibodies upon binding to soluble protein. The latter protocol has been optimized to allow an increased throughput, as potential applications require large numbers of samples. Both approaches can be completed in a day.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field.

              Designing tight-binding ligands is a primary objective of small-molecule drug discovery. Over the past few decades, free-energy calculations have benefited from improved force fields and sampling algorithms, as well as the advent of low-cost parallel computing. However, it has proven to be challenging to reliably achieve the level of accuracy that would be needed to guide lead optimization (∼5× in binding affinity) for a wide range of ligands and protein targets. Not surprisingly, widespread commercial application of free-energy simulations has been limited due to the lack of large-scale validation coupled with the technical challenges traditionally associated with running these types of calculations. Here, we report an approach that achieves an unprecedented level of accuracy across a broad range of target classes and ligands, with retrospective results encompassing 200 ligands and a wide variety of chemical perturbations, many of which involve significant changes in ligand chemical structures. In addition, we have applied the method in prospective drug discovery projects and found a significant improvement in the quality of the compounds synthesized that have been predicted to be potent. Compounds predicted to be potent by this approach have a substantial reduction in false positives relative to compounds synthesized on the basis of other computational or medicinal chemistry approaches. Furthermore, the results are consistent with those obtained from our retrospective studies, demonstrating the robustness and broad range of applicability of this approach, which can be used to drive decisions in lead optimization.
                Bookmark

                Author and article information

                Contributors
                Journal
                Proc Natl Acad Sci U S A
                Proc Natl Acad Sci U S A
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                4 January 2023
                10 January 2023
                4 January 2023
                : 120
                : 2
                : e2212931120
                Affiliations
                [1] aDepartment of Pharmaceutical Chemistry, University of California San Francisco , San Francisco, CA 94158
                [2] bDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco , San Francisco, CA 94158
                [3] cSir William Dunn School of Pathology, University of Oxford , Oxford OX1 3RE, UK
                [4] dWellcome Centre for Human Genetics, University of Oxford , Oxford OX3 7BN, UK
                [5] eNational Institute for Health Research Oxford Biomedical Research Centre , Oxford OX4 2PG, UK
                [6] fHelen Diller Family Comprehensive Cancer Center, University of California San Francisco , San Francisco, CA 94158
                [7] gInstitute for Neurodegenerative Disease, University of California San Francisco , San Francisco, CA 94158
                [8] hChemistry and Chemical Biology Graduate Program, University of California San Francisco , San Francisco, CA 94158
                [9] iDepartment of Pharmaceutical Chemistry and Small Molecule Discovery Center, University of California , San Francisco, CA 94158
                [10] jDiamond Light Source Ltd., Harwell Science and Innovation Campus , Didcot OX11 0DE, UK
                [11] kResearch Complex at Harwell Harwell Science and Innovation Campus , Didcot OX11 0FA, UK
                [12] lEnamine Ltd. , Kyiv 02094, Ukraine
                [13] mTaras Shevchenko National University of Kyiv , Kyiv 01601, Ukraine
                [14] nChemspace , Kyiv 02094, Ukraine
                [15] oCentre for Medicines Discovery, University of Oxford , Headington OX3 7DQ, UK
                [16] pStructural Genomics Consortium, University of Oxford , Headington OX3 7DQ, UK
                [17] qDepartment of Biochemistry, University of Johannesburg , Auckland Park 2006, South Africa
                Author notes
                2To whom correspondence may be addressed. Email: bshoichet@ 123456gmail.com or jfraser@ 123456fraserlab.com .

                Edited by Lila Gierasch, University of Massachusetts Amherst, Amherst, MA; received July 27, 2022; accepted November 28, 2022

                1S.G. and G.J.C. contributed equally to this work.

                Author information
                https://orcid.org/0000-0002-3115-9757
                https://orcid.org/0000-0002-5508-4673
                https://orcid.org/0000-0002-3388-7803
                https://orcid.org/0000-0003-3671-8885
                https://orcid.org/0000-0001-5900-3060
                https://orcid.org/0000-0002-2247-9345
                https://orcid.org/0000-0003-3529-7863
                https://orcid.org/0000-0001-5444-7754
                https://orcid.org/0000-0001-6073-002X
                https://orcid.org/0000-0002-1240-2846
                https://orcid.org/0000-0003-3602-5704
                https://orcid.org/0000-0003-0378-0017
                https://orcid.org/0000-0002-6098-7367
                https://orcid.org/0000-0002-5080-2859
                Article
                202212931
                10.1073/pnas.2212931120
                9926234
                36598939
                9674cb3b-f7fa-4553-a350-f2a7dcddc809
                Copyright © 2023 the Author(s). Published by PNAS.

                This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

                History
                : 27 July 2022
                : 28 November 2022
                Page count
                Pages: 12, Words: 9219
                Funding
                Funded by: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), FundRef 100000060;
                Award ID: U19AI171110
                Award Recipient : Adam R. Renslo Award Recipient : Alan Ashworth Award Recipient : Brian K. Shoichet Award Recipient : James S Fraser
                Funded by: NSF | BIO | Division of Biological Infrastructure (DBI), FundRef 100000153;
                Award ID: 2031205
                Award Recipient : James S Fraser
                Funded by: HHS | NIH | National Institute of General Medical Sciences (NIGMS), FundRef 100000057;
                Award ID: R35GM122481
                Award Recipient : John J Irwin Award Recipient : Jason Gestwicki Award Recipient : Brian K. Shoichet
                Funded by: DOD | Defense Advanced Research Projects Agency (DARPA), FundRef 100000185;
                Award ID: HR0011-19-2-0020
                Award Recipient : Brian K. Shoichet
                Funded by: HHS | NIH | National Institute of General Medical Sciences (NIGMS), FundRef 100000057;
                Award ID: GM141299
                Award Recipient : John J Irwin Award Recipient : Jason Gestwicki Award Recipient : Brian K. Shoichet
                Funded by: HHS | NIH | National Institute of General Medical Sciences (NIGMS), FundRef 100000057;
                Award ID: GM133836
                Award Recipient : John J Irwin Award Recipient : Jason Gestwicki Award Recipient : Brian K. Shoichet
                Funded by: HHS | NIH | National Institute of General Medical Sciences (NIGMS), FundRef 100000057;
                Award ID: GM071896
                Award Recipient : John J Irwin Award Recipient : Jason Gestwicki Award Recipient : Brian K. Shoichet
                Categories
                dataset, Dataset
                research-article, Research Article
                covid-19, Coronavirus (COVID-19)
                biophys-bio, Biophysics and Computational Biology
                408
                530
                Biological Sciences
                Biophysics and Computational Biology
                Custom metadata
                free

                coronavirus,macrodomain,virtual screening,fragment-based drug discovery

                Comments

                Comment on this article